Skip to content

Generate Biomedicines

US · GENB #2875 by market cap Listed 2026
9.54 -0.83 -8.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:32

Valuation each multiple against its own 5-year range

P/B ratio 4.09 Expensive vs history 75th percentile
5-year average 2.07 · #358 of 514 in Biotechnology
P/E ratio -6.36 Expensive vs history 69th percentile
5-year average -6.74 · forward -4.11
P/S ratio 73.96 Expensive vs history 83rd percentile
5-year average 60.78 · forward 53.52 · #278 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Generate Biomedicines (GENB) 1.23B -5.03 3.23 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value16.33 Economic moatNone UncertaintyVery High

Trading 71.2% below Morningstar's fair value estimate.

Fair value

Generate Biomedicines Inc is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 26% discount to our quantitative fair value estimate of $16.33 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics bolster our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 3.7, which ranks in the bottom 40% compared with global peers. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 2.0%, a core component of profitability, sits in the bottom 10% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:32:29 · For reference only, not investment advice and not tailored to your situation.

Generate Biomedicines discussion 0 comments

Add a comment